Japanese journal of gastroenterology and hepatology · 2026
Prognostic Factor and Serum Biomarker Changes in Non-Surgical Hepatocellular Carcinoma Patients Treated with Radioembolization.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Carr B I, Gozukara Bag H G, Kutlu R, Karabulut E, Ince V, Yilmaz S
Аннотация
BACKGROUND: 1.1:Transarterial radioembolization (TARE) with 90Y is a primary therapy for hepatocellular carcinoma (HCC), including patients with portal vein thrombosis (PVT). Patient survival subgroups post TARE have not been clearly defined.
AIMS: 1.2.To identify prognostic factors in patients treated with TARE.
METHODS: 1.3.Non-surgical HCC patients (n=116) were treated with TARE and prospectively followed for survival and changes in blood parameters relating to inflammation and tumor indices.
RESULTS: 1.4.Baseline parameters with the highest hazard ratios (HR>2) for survival were C-reactive protein, alpha-fetoprotein (AFP), maximum tumor diameter (MTD) and PVT. A 2-parameter prognostic model was developed, consisting of serum AFP and C-reactive protein, which was especially significant in patients with PVT. Temporal changes post TARE in ALBI and serum gamma glutamyl transferase (GGT) levels occurred in patients with both high and low serum AFP. A network phenotyping strategy (NPS) showed that patient phenotypes also change after TARE. Post TARE reduction in AFP or GGT or increase in albumin levels were associated with improved survival.
CONCLUSIONS: 1.5.Changes in serum CRP, AFP, GGT, albumin, ALBI, and NPS phenotype occurred early after TARE. Changes in AFP, GGT and albumin related to survival and may be useful in selecting patients for additional treatment.
AIMS: 1.2.To identify prognostic factors in patients treated with TARE.
METHODS: 1.3.Non-surgical HCC patients (n=116) were treated with TARE and prospectively followed for survival and changes in blood parameters relating to inflammation and tumor indices.
RESULTS: 1.4.Baseline parameters with the highest hazard ratios (HR>2) for survival were C-reactive protein, alpha-fetoprotein (AFP), maximum tumor diameter (MTD) and PVT. A 2-parameter prognostic model was developed, consisting of serum AFP and C-reactive protein, which was especially significant in patients with PVT. Temporal changes post TARE in ALBI and serum gamma glutamyl transferase (GGT) levels occurred in patients with both high and low serum AFP. A network phenotyping strategy (NPS) showed that patient phenotypes also change after TARE. Post TARE reduction in AFP or GGT or increase in albumin levels were associated with improved survival.
CONCLUSIONS: 1.5.Changes in serum CRP, AFP, GGT, albumin, ALBI, and NPS phenotype occurred early after TARE. Changes in AFP, GGT and albumin related to survival and may be useful in selecting patients for additional treatment.